Lexaria Bioscience (LEXX) Competitors $0.58 +0.02 (+3.07%) Closing price 04:00 PM EasternExtended Trading$0.60 +0.02 (+4.11%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. IMA, PDSB, TIL, IBIO, and KZRShould you buy Lexaria Bioscience stock or one of its competitors? MarketBeat compares Lexaria Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexaria Bioscience include ImageneBio (IMA), PDS Biotechnology (PDSB), Instil Bio (TIL), iBio (IBIO), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. LEXX vs. IMALEXX vs. PDSBLEXX vs. TILLEXX vs. IBIOLEXX vs. KZRHow does Lexaria Bioscience compare to ImageneBio?ImageneBio (NASDAQ:IMA) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Do analysts rate IMA or LEXX? ImageneBio currently has a consensus price target of $26.50, indicating a potential upside of 404.76%. Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 159.83%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.00Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is IMA or LEXX more profitable? ImageneBio has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. ImageneBio's return on equity of -38.96% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets ImageneBioN/A -38.96% -34.60% Lexaria Bioscience -1,685.84%-206.02%-162.53% Do institutionals and insiders believe in IMA or LEXX? 75.0% of ImageneBio shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 5.9% of ImageneBio shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, IMA or LEXX? Lexaria Bioscience has lower revenue, but higher earnings than ImageneBio. Lexaria Bioscience is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImageneBio$800K69.89-$45.35M-$5.79N/ALexaria Bioscience$710K20.16-$11.90M-$0.47N/A Does the media favor IMA or LEXX? In the previous week, ImageneBio had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for ImageneBio and 0 mentions for Lexaria Bioscience. ImageneBio's average media sentiment score of 0.36 beat Lexaria Bioscience's score of 0.00 indicating that ImageneBio is being referred to more favorably in the media. Company Overall Sentiment ImageneBio Neutral Lexaria Bioscience Neutral Which has more risk and volatility, IMA or LEXX? ImageneBio has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. SummaryImageneBio beats Lexaria Bioscience on 12 of the 16 factors compared between the two stocks.How does Lexaria Bioscience compare to PDS Biotechnology?PDS Biotechnology (NASDAQ:PDSB) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Is PDSB or LEXX more profitable? PDS Biotechnology has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. Lexaria Bioscience's return on equity of -206.02% beat PDS Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -346.02% -102.36% Lexaria Bioscience -1,685.84%-206.02%-162.53% Do analysts prefer PDSB or LEXX? PDS Biotechnology currently has a consensus price target of $9.00, indicating a potential upside of 800.00%. Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 159.83%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, PDSB or LEXX? PDS Biotechnology has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Does the media prefer PDSB or LEXX? In the previous week, PDS Biotechnology had 14 more articles in the media than Lexaria Bioscience. MarketBeat recorded 14 mentions for PDS Biotechnology and 0 mentions for Lexaria Bioscience. PDS Biotechnology's average media sentiment score of 0.73 beat Lexaria Bioscience's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Overall Sentiment PDS Biotechnology Positive Lexaria Bioscience Neutral Do institutionals and insiders believe in PDSB or LEXX? 26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings & valuation, PDSB or LEXX? Lexaria Bioscience has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$34.50M-$0.67N/ALexaria Bioscience$710K20.16-$11.90M-$0.47N/A SummaryPDS Biotechnology beats Lexaria Bioscience on 10 of the 15 factors compared between the two stocks.How does Lexaria Bioscience compare to Instil Bio?Instil Bio (NASDAQ:TIL) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Which has better earnings & valuation, TIL or LEXX? Lexaria Bioscience has higher revenue and earnings than Instil Bio. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$71.37M-$7.08N/ALexaria Bioscience$710K20.16-$11.90M-$0.47N/A Is TIL or LEXX more profitable? Instil Bio has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. Instil Bio's return on equity of -39.76% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -39.76% -22.38% Lexaria Bioscience -1,685.84%-206.02%-162.53% Which has more volatility and risk, TIL or LEXX? Instil Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Do analysts prefer TIL or LEXX? Instil Bio currently has a consensus price target of $66.00, indicating a potential upside of 722.94%. Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 159.83%. Given Instil Bio's higher probable upside, analysts clearly believe Instil Bio is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer TIL or LEXX? In the previous week, Instil Bio had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for Instil Bio and 0 mentions for Lexaria Bioscience. Instil Bio's average media sentiment score of 0.50 beat Lexaria Bioscience's score of 0.00 indicating that Instil Bio is being referred to more favorably in the media. Company Overall Sentiment Instil Bio Positive Lexaria Bioscience Neutral Do institutionals and insiders believe in TIL or LEXX? 60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryInstil Bio beats Lexaria Bioscience on 10 of the 15 factors compared between the two stocks.How does Lexaria Bioscience compare to iBio?Lexaria Bioscience (NASDAQ:LEXX) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Does the media prefer LEXX or IBIO? In the previous week, iBio had 14 more articles in the media than Lexaria Bioscience. MarketBeat recorded 14 mentions for iBio and 0 mentions for Lexaria Bioscience. iBio's average media sentiment score of 0.44 beat Lexaria Bioscience's score of 0.00 indicating that iBio is being referred to more favorably in the news media. Company Overall Sentiment Lexaria Bioscience Neutral iBio Neutral Which has more risk & volatility, LEXX or IBIO? Lexaria Bioscience has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, iBio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Which has preferable earnings & valuation, LEXX or IBIO? Lexaria Bioscience has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$710K20.16-$11.90M-$0.47N/AiBio$300K180.72-$18.38M-$0.58N/A Do insiders & institutionals believe in LEXX or IBIO? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend LEXX or IBIO? Lexaria Bioscience presently has a consensus price target of $1.50, indicating a potential upside of 159.83%. iBio has a consensus price target of $4.75, indicating a potential upside of 216.67%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00iBio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.17 Is LEXX or IBIO more profitable? iBio has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. iBio's return on equity of -53.86% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,685.84% -206.02% -162.53% iBio N/A -53.86%-46.48% SummaryiBio beats Lexaria Bioscience on 11 of the 17 factors compared between the two stocks.How does Lexaria Bioscience compare to Kezar Life Sciences?Lexaria Bioscience (NASDAQ:LEXX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation. Which has more risk & volatility, LEXX or KZR? Lexaria Bioscience has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Kezar Life Sciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Is LEXX or KZR more profitable? Kezar Life Sciences has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. Kezar Life Sciences' return on equity of -55.42% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,685.84% -206.02% -162.53% Kezar Life Sciences N/A -55.42%-47.87% Do analysts prefer LEXX or KZR? Lexaria Bioscience presently has a consensus price target of $1.50, indicating a potential upside of 159.83%. Kezar Life Sciences has a consensus price target of $6.00, indicating a potential downside of 17.70%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Lexaria Bioscience is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Kezar Life Sciences 2 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Does the media prefer LEXX or KZR? In the previous week, Kezar Life Sciences had 3 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Kezar Life Sciences and 0 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.00 beat Kezar Life Sciences' score of -0.33 indicating that Lexaria Bioscience is being referred to more favorably in the media. Company Overall Sentiment Lexaria Bioscience Neutral Kezar Life Sciences Neutral Which has stronger valuation & earnings, LEXX or KZR? Lexaria Bioscience has higher revenue and earnings than Kezar Life Sciences. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$710K20.16-$11.90M-$0.47N/AKezar Life SciencesN/AN/A-$56.03M-$6.17N/A Do insiders and institutionals have more ownership in LEXX or KZR? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryKezar Life Sciences beats Lexaria Bioscience on 8 of the 15 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition ExportMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.88M$3.25B$6.25B$12.23BDividend YieldN/A2.34%2.80%5.32%P/E Ratio-1.2318.5220.7925.05Price / Sales20.16270.32531.2172.69Price / CashN/A124.5843.0954.25Price / Book4.446.609.816.83Net Income-$11.90M$24.18M$3.55B$335.69M7 Day Performance0.09%-3.56%-2.07%-2.03%1 Month Performance-43.95%-7.86%-3.90%-1.90%1 Year Performance-42.27%51.80%29.39%27.36% Lexaria Bioscience Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience2.2609 of 5 stars$0.58+3.1%$1.50+159.8%-44.5%$13.88M$710KN/A7Gap UpIMAImageneBio2.7042 of 5 stars$5.25-7.1%$26.50+404.8%-57.6%$55.93MN/AN/A70Analyst DowngradePDSBPDS Biotechnology3.4141 of 5 stars$1.00-15.3%$9.00+800.0%-16.9%$55.82MN/AN/A20Earnings ReportAnalyst RevisionHigh Trading VolumeTILInstil Bio2.1833 of 5 stars$8.02-1.4%$66.00+722.9%-44.4%$54.38MN/AN/A410Earnings ReportAnalyst DowngradeIBIOiBio4.2675 of 5 stars$1.50+5.6%$4.75+216.7%N/A$54.21M$400KN/A100Earnings ReportAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies IMA Competitors PDSB Competitors TIL Competitors IBIO Competitors KZR Competitors CING Competitors BYSI Competitors INKT Competitors SCLX Competitors XLO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
